Crown Bioscience, one of CID Fund III portfolios, was sucessfully transferred from Emerging Board of Taipei Exchange to the Main Board
Dec 12, 2016
The CID Group (“CID”) is pleased to announce that Crown Bioscience Ltd. (“Crown Bio” or “the Company”), a leading global drug discovery and preclinical development service company, has successfully transferred to the Main Board from the Emerging Board of Taipei Exchange on December 12th, 2016. (Stock Code: 6554 TT)
Headquartered in Silicon Valley with research facilities in the United States, United Kingdom, mainland China and Taiwan, the Company provides cutting-edge translational platforms helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. With the world's largest commercial collection of validated Patient-Derived Xenograft (PDX) models, the company can help the biopharmaceutical clients accelerate their new drug development programs significantly.
CID invested in Crown Bio in 2011 and helped the company list on the Emerging Board of Taipei Exchange in February 2016. The Company continued to deliver strong growth and passed all the requirements of listing on the Main Board within less than 10 months. The Company posted net income of NTD 96 million on revenues of NTD 1.3 billion for the first three quarters of 2016, marking 42% growth in revenue compared to the same period last year. Based on the closing price of the first trading day, the market cap of CrownBio is NTD 7.5 billion which achieved 2.0x multiple and 12% IRR for CID’s investment.
For more than 16 years, CID has been focused on venture investments and industry integration opportunities in the Greater China market. CID has invested in 189 companies and achieved 99 exits. In the healthcare sector, CID has 15 portfolio companies across mainland China, Taiwan and the US, and has achieved 4 IPO and 1 M&A exits.
Successfully listed on China's National Equities, Transn is a leading multi-language translation service provider in China
Mar 3, 2016
The CID Group (“CID”) is pleased to announce the successful listing of “Transn (China) Technology Co.,Ltd (“Transn”), on China’s National Equities Exchange and Quotations (NEEQ), known as “New Third Board” (Stock Code: 835737.NE) on February 29th, 2016.
Founded in 2005, Transn is a leading multi-language translation service provider in China. Pioneered in integrating big data and language processing technology, the company built Asia’s first “Cloud Translation Service Platform” partnering with more than 600,000 translators and interpreters and over 1,000 translation companies from all over the world. Transn’s internet based platform can translate over 30 languages with a daily average output of 10 million words.
Transn received numerous awards including China’s “National High and New Technology Enterprises”. It has filed more than 130 patents and 60 software copyrights by now. The company has serviced thousands of local and multinational corporate clients, and supported national activities such as Beijing Olympic Games, Shanghai World Expo, etc. Transn is also the only inspection-free partner of CCTV4 and a major language service provider for multiple ministries and commissions of China. As of September 2015, the Company posted revenue of RMB 167 million and achieved more than 30% growth rate almost every year since the inception.
CID Greater China Venture Capital Fund II, L.P. invested in the A-round in 2007 and held approximately 15% of the Company. As one of the largest institutional shareholders of the Company, CID has been working closely with Transn in shaping its business strategy of B2B business model and “Internet of Language” platform. CID is proud to be a partner of the highly innovative and capable team, and achieve this milestone poised for greater success in the future.
For more than 18 years, CID has been focused on venture investments and industry integration opportunities in the Greater China market. CID has invested in 187 companies and achieved 97 exits.
Crown Bio, a leading global drug discovery and preclinical development service company, was sucessfully listed on Emerging Stock Market of Taipei Exchange
Feb 18, 2016
The CID Group (“CID”) is pleased to announce the successful listing of Crown Bioscience Ltd. (“Crown Bio” or “the Company”), one of CID Greater China Venture Capital Fund III, L.P.’s (“Fund”) portfolio companies, on the Emerging Stock Market of Taipei Exchange (Stock Code: 6554 TT) on February 18th, 2016.
Headquartered in Silicon Valley, with operations and research services mainly performed by its wholly owned research facilities in China, Crown Bio is a leading global drug discovery and preclinical development service company. The Company provides cutting-edge translational platforms and cost effective drug discovery solutions, focusing on oncology and metabolic disease therapeutic areas, to its global biotech and pharmaceutical partners. The Company has the largest and most comprehensive collection of clinically and ethnically diverse PDX (patient-derived xenograft) cancer models in the world. The Company achieved net profit of NTD 152 million as of November 2015, after the recorded annual loss of NTD 363 million in 2013 and NTD 277 million in 2014.
CID invested in Crown Bio in 2011. Since the inception of investment, CID has been actively supporting the Company’s business development. Starting in 2014, CID helped the company in shaping its fundraising strategy and introducing the company to Taiwan’s capital market. Crownbio marked CID’s 5th cross-strait IPO including 4 China-based companies listed in Taiwan and one Taiwan-based company listed in China, demonstrating the firm’s unique capability in formulating a dynamic and optimal exit strategy for the portfolio companies.
CID now has 14 portfolio companies in healthcare sector across China, Taiwan and the US, and has achieved 3 IPO and 1 M&A exits. On the first day of trading, the Crown Bio’s stock price surged 100% above its listing price of NTD 45 and closed at NTD 74. The closing market cap of the Company is NTD9.7 billion (US$291 million). Based on the closing price, CID has achieved 2.5x multiple and 21% IRR for the investment.
For more than 16 years, CID has been focused on venture investments and industry integration opportunities in the Greater China market. CID has invested in 186 companies and achieved 96 exits.
Rooted in Taiwan and expanded in China, Thai Ho was sucessfully listed on the Emerging Stock Market of Taipei Exchange
Jan 27, 2016
The CID Group (“CID”) is pleased to announce the successful listing of Thai Ho Group Inc. (“Thai Ho” or “the Company”), one of CID Greater China Venture Capital Fund II, L.P.’s (“Fund”) portfolio companies, on the Emerging Stock Market of Taipei Exchange (Stock Code: F-4136 TT) on January 27th, 2016.
Rooted in Taiwan since 1980 and expanded in China in the early 1990s, Thai Ho is the world’s third largest cosmetic manufacturing group supplying global leading cosmetic brands such as Elizabeth Arden, Avon, Boots, etc. With more than 30 years of skincare and cosmetic manufacturing expertise, the Company’s products have achieved the standard and accreditation of United States FDA, the European EEC, Swedish SGS GMP, and passed Swedish SA8000 certification, SGS ISO 9001 quality system certification, and the accreditations from Japan and Australia. The Company posted the revenues of NT$907 million in 2015, marking growth of more than 38% over the same period last year.
This investment demonstrated CID’s investment strategy of bridging Taiwanese enterprise with the China market. Since the investment in 2009., CID has been actively assisting the Company in shaping its business development, penetrating its client base and IPO preparation. CID invested US$10.8 million in Thai Ho, representing 17% ownership of the Company. Thai Ho is the first beauty care product manufacturer listing in Taiwan. On the first day of trading, the Company’s stock price closed at the highest price of NTD 61.5, more than 36% above its listing price of NTD 45. The closing market cap of the Company is NTD1.5 billion (US$44 million).
For more than 16 years, CID has been focused on venture investments and industry integration opportunities in the Greater China market. CID has invested in 185 companies and achieved 95 exits.